Gliomas are cancers that start in the glial cells of the nervous system and account for nearly one-third of all brain tumors. Glioblastoma is the most aggressive type of glioma and is virtually incurable.

The epidermal growth factor receptor (EGFR) signaling pathway was previously known to be highly active in most glioblastomas. Signaling pathways are cellular "chains of command" through which a string of proteins is sequentially triggered to stimulate a specific cell function. The irregular activation of certain pathways often leads to disease, including cancer.

Blocking the function of the EGFR pathway was previously found to promote senescence, a mechanism critical in stunting the growth and spread of cancer cells. Massey researchers discovered that a specific protein called ubiquitin-specific protease 16 (USP16) regulates senescence and mitigates glioma cell growth.

The researchers also identified a separate strand of long noncoding RNA called lncEPAT that is activated through EGFR and is highly functional in glioblastoma. Their findings suggest that lncEPAT acts as a genetic moderator, allowing EGFR to escape the antitumor role of USP16 and fuel cancer progression. Preclinical models showed that the depletion of lncEPAT increased the activity of USP16 and stifled glioblastoma cell growth.

"We have compelling evidence that lncEPAT's cancer-driving function in glioblastoma is dependent on the inactivation of the USP16 protein," study author Dr. Suyun Huang, PhD, chair of cancer research at Massey, said in a statement. "EGFR-induced, overexpressed lncEPAT provides a promising new target for pro-senescence treatment for glioblastoma."

Small molecule drug first to target circadian clock proteins to treat glioblastoma
A new type of small molecule drug is the first to target circadian clock proteins that play a key role in the spread of the deadly cancer glioblastoma,...

NIH funds repurposing of breast cancer drug against glioblastoma
The National Institutes of Health (NIH) is funding research into the repurposing of the breast cancer drug letrozole for use against the most deadly form...

Combination therapy improves survival in mice with deadly glioblastoma
Combining an antidepressant and vascular endothelial growth factor inhibitor improves outcomes in mouse models of a hard-to-treat type of brain cancer,...

Researchers find how EGFR sends signals into cells, could help cancer drug design
Chemists at the Massachusetts Institute of Technology have revealed how the epidermal growth factor receptor (EGFR) changes its shape when it binds to...